Skip Navigation LinksHome > December 2011 - Volume 17 - Issue 6, Secondary Stroke Prevention > Cryptogenic Stroke and Patent Foramen Ovale
CONTINUUM: Lifelong Learning in Neurology:
doi: 10.1212/01.CON.0000410039.72594.03
Practice Issues

Cryptogenic Stroke and Patent Foramen Ovale

Jaigobin, Cheryl MD

Collapse Box

Abstract

ABSTRACT: In patients with cryptogenic stroke and patent foramen ovale, options for stroke prevention include medical therapy (antiplatelet therapy or anticoagulation) and percutaneous device closure. In the only completed randomized controlled trial comparing medical therapy and percutaneous device closure, there was no difference in outcome between the two forms of treatment, and both are viable options for stroke prevention. The choice of therapy is made after careful weighing of potential risks and benefits associated with each form of therapy based on the limited evidence to date and the anticipated patient adherence with the planned treatment. Participation in a clinical trial is a third option for these patients.

© 2011 American Academy of Neurology

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login